This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Luis A. García Rodríguez, MD, MSc
Madrid, Spain

Bruno H. Stricker, MD
Rotterdam, the Netherlands

Hyman J. Zimmerman, MD
Washington, DC

Arch Intern Med. 1997;157(3):358.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Our response to the comments included in the letter by Fletcher and colleagues have already been previously submitted to the manufacturer of amoxicillin and clavulanate potassium (Augmentin, SmithKline Beecham Pharmaceuticals, Philadelphia, Pa). Two of the authors of this letter have been consultants for this drug company and have reviewed our data at the company's request. In summary, the reply to all concerns raised by Fletcher and colleagues is as follows:

• Table 4 presents stratified analyses for age, concurrent hepatotoxic drugs, and duration of treatment. The results clearly show that adjusting for these factors further increases the relative risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid.
  
• As stated in our article, we adapted the criteria of the consensus publication such that when the values for alanine aminotransferase were not available we used those for aspartate aminotransferase instead. Also, as we stated, agreement on
  

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?